{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:32:43Z","timestamp":1772713963358,"version":"3.50.1"},"reference-count":34,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Clinical Trials"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1310\/hct0801-9","type":"journal-article","created":{"date-parts":[[2007,4,12]],"date-time":"2007-04-12T15:47:39Z","timestamp":1176392859000},"page":"9-18","source":"Crossref","is-referenced-by-count":7,"title":["Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort"],"prefix":"10.1080","volume":"8","author":[{"given":"Franco","family":"Maggiolo","sequence":"first","affiliation":[{"name":"Divisione di Malattie Infettive"},{"name":"Unit\u00e0 di Terapia Antivirale"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"},{"name":"Unit\u00e0 di Terapia Antivirale"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Airoldi","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annapaola","family":"Callegaro","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologiae Virologia, Ospedali Riuniti, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Arici","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Ravasio","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Bombana","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Goglio","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologiae Virologia, Ospedali Riuniti, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredy","family":"Suter","sequence":"additional","affiliation":[{"name":"Divisione di Malattie Infettive"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.12.930"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412501"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00015"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"issue":"3","key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleo-tide analogue drug exposure.","volume":"6","author":"Miller V","year":"2001","unstructured":"Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleo-tide analogue drug exposure. Antiviral Ther 2001;6\\(suppl 3):25\u201344.","journal-title":"Antiviral Ther"},{"key":"e_1_2_1_7_1","first-page":"600","article-title":"for the Adult ACTG 306 and 370 Teams","volume":"36","author":"Kuritzkes DR","year":"2004","unstructured":"Kuritzkes DR, Basset RL, Hazelwood D, Barret H, Rhodes RA, Young RK, Johnson VA, for the Adult ACTG 306 and 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regi-mens. J Acquir Immune Defic Syndr 2004;36:600\u2013603.","journal-title":"Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regi-mens. J Acquir Immune Defic Syndr"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199610090-00007"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200006160-00017"},{"key":"e_1_2_1_10_1","first-page":"162","article-title":"Calves V","volume":"72","author":"Marcelin AG","year":"2004","unstructured":"Marcelin AG, Delaguerre C, Wirden M, Viegas P, Simon A, Katlama C, Calves V. Thymidine analogue reverse tran-scriptase inhibitors resistance mutations profiles and asso-ciation to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol. 2004;72:162\u2013165.","journal-title":"Thymidine analogue reverse tran-scriptase inhibitors resistance mutations profiles and asso-ciation to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000137005.63376.6e"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030265"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199902040-00002"},{"issue":"4","key":"e_1_2_1_14_1","first-page":"S28","article-title":"Ritonavir\/amprenavir combination therapy in HIV infected patients who failed several prote-ase inhibitor containing regimens.","volume":"14","author":"Katlama C","year":"2000","unstructured":"Katlama C, Schneider L, Agher R, Delaguerre C, Calvez V, Legrand M, Tubiana R. Ritonavir\/amprenavir combination therapy in HIV infected patients who failed several prote-ase inhibitor containing regimens. AIDS. 2000;14\\(suppl 4): S28.","journal-title":"AIDS"},{"key":"e_1_2_1_15_1","first-page":"1001","article-title":"Katzen-stein D, Albrecht M, De Gruttola V","volume":"188","author":"Jiang H","year":"2003","unstructured":"Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzen-stein D, Albrecht M, De Gruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001\u20131008.","journal-title":"Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis"},{"key":"e_1_2_1_16_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.qai.0000197070.69859.f3","article-title":"Minimizing re-sistance consequences after virologic failure on initial com-bination therapy: a systematic overview.","volume":"41","author":"Bartlett JA","year":"2006","unstructured":"Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing re-sistance consequences after virologic failure on initial com-bination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006;41:323\u2013331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_1_17_1","unstructured":"Maggiolo F Callegaro A Airoldi M Ravasio V Ripamonti D Gregis G Suter F. Evaluation of 3 expert systems for genotypic analysis. In: Program and abstracts of the Eighth International Congress on Drug Therapy in HIV Infection; November 2006; Glasgow UK. Abstract P213."},{"key":"e_1_2_1_18_1","unstructured":"Centers for Disease Control and Prevention. 1993 revised system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:9\u201312."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00002"},{"key":"e_1_2_1_20_1","first-page":"185","article-title":"Reasons for modifica-tion and discontinuation of antiretrovirals: results from a single treatment centre.","volume":"200115","author":"Mocroft A","unstructured":"Mocroft A, Youle M, Moore A, et al. Reasons for modifica-tion and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 200115: 185\u2013194.","journal-title":"AIDS"},{"key":"e_1_2_1_21_1","unstructured":"Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-infected adults and adolescents. November 10 2003. Available at: www.hivatis.org. Last accessed January 2006."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/375355"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00131.x"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350300800308"},{"key":"e_1_2_1_25_1","first-page":"404","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.","volume":"40","author":"Nelson M","year":"2005","unstructured":"Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. JAIDS. 2005;40:404\u2013412.","journal-title":"JAIDS"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1310\/2XVK-PBGL-735N-WH72"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1310\/0XH7-F2V2-1K0R-NU2W"},{"key":"e_1_2_1_28_1","unstructured":"Stanford University. Stanford HIV Drug Resistance Da-tabase. Available at: http:\/\/hivdb.stanford.edu. Last ac-cessed June 30 2006."},{"key":"e_1_2_1_29_1","unstructured":"Maggiolo F Callegaro A Ripamonti D et al. Genotypic mutations in patients failing HAART with low level viremia. Presented at: 16th IAC; August 2006; Toronto Canada. Ab-stract THPE0100."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/088922201316912718"},{"issue":"1","key":"e_1_2_1_31_1","first-page":"S36\u2014S43","article-title":"Resistance issues with new nu-cleoside\/nucleotide backbone options.","volume":"37","author":"Wainberg MA","year":"2004","unstructured":"Wainberg MA, Turner D. Resistance issues with new nu-cleoside\/nucleotide backbone options. J Acquir Immune Defic Syndr 2004;37\\(suppl 1):S36\u2014S43.","journal-title":"J Acquir Immune"},{"issue":"3","key":"e_1_2_1_32_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350100603S03","article-title":"Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue exposure.","volume":"6","author":"Miller V","year":"2001","unstructured":"Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue exposure. Antiviral Ther 2001 ;6\\(suppl 3):25\u201344.","journal-title":"Antiviral Ther"},{"issue":"3","key":"e_1_2_1_33_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/135965350100603S04","article-title":"A rationale approach to the selection and se-quencing of nucleoside\/nucleotide analogues: a new para-digm.","volume":"6","author":"Lange J","year":"2001","unstructured":"Lange J. A rationale approach to the selection and se-quencing of nucleoside\/nucleotide analogues: a new para-digm. Antiviral Ther 2001;6\\(suppl 3):45\u201354.","journal-title":"Antiviral Ther"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000216371.76689.63"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409240-00005"}],"container-title":["HIV Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1310\/hct0801-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:42:48Z","timestamp":1772710968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1310\/hct0801-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1310\/hct0801-9"],"URL":"https:\/\/doi.org\/10.1310\/hct0801-9","relation":{},"ISSN":["1528-4336","1945-5771"],"issn-type":[{"value":"1528-4336","type":"print"},{"value":"1945-5771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}